Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy

被引:58
作者
Firat, H
Zennou, V
Garcia-Pons, F
Ginhoux, F
Cochet, M
Danos, O
Lemonnier, FA
Langlade-Demoyen, P
机构
[1] CNRS, URA 1923, Genethon III, F-91002 Evry, France
[2] CNRS, URA 1923, Unite Immunite Cellulaire Antivirale, F-91002 Evry, France
[3] Inst Pasteur, Dept Mol Med, Grp Virol Mol & Vectorol, F-75724 Paris, France
关键词
HIV-1; vector; dendritic cells; cancer immunotherapy; CTL; melanoma;
D O I
10.1002/jgm.243
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background A central triple-stranded DNA structure created during HIV-1 reverse transcription, the central flap, acts as a cis-active nuclear import determinant of the HIV-1 DNA genome. Insertion of the sequences responsible for formation of the central DNA flap into an HIV-1-derived vector strongly enhances its transduction efficiency. Methods HIV-1 vectors with or without inclusion of the DNA flap and encoding the same melanoma polyepitope were constructed to transduce dendritic cells (DCs) and to evaluate their capacity for induction of melanoma-specific cytotoxic T-lymphocyte (CTL) responses ex vivo and in vivo. Results HIV-1 vectors including the DNA flap transduced up to 100% of immature mouse and human DCs. Inoculation of HLA-A2.1 transgenic mice with this flap vector elicited vigorous and multi-specific long-term anti-melanoma CTL responses, whereas the parental vector lacking the flap sequence was less efficient. Furthermore, human DCs transduced ex vivo with the recombinant DNA flap vector displayed efficient multi-specific primary human CTL responses against melanoma. Conclusion Lentiviral vectors including the DNA flap should be powerful tools both for active immunization and for the ex vivo priming of CTL for tumor immunotherapy. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 28 条
[1]   Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires [J].
Bousso, P ;
Casrouge, A ;
Altman, JD ;
Haury, M ;
Kanellopoulos, J ;
Abastado, JP ;
Kourilsky, P .
IMMUNITY, 1998, 9 (02) :169-178
[2]   Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity [J].
Celluzzi, CM ;
Mayordomo, JI ;
Storkus, WJ ;
Lotze, MT ;
Falo, LD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :283-287
[3]   HIV-1 REVERSE TRANSCRIPTION - A TERMINATION STEP AT THE CENTER OF THE GENOME [J].
CHARNEAU, P ;
MIRAMBEAU, G ;
ROUX, P ;
PAULOUS, S ;
BUC, H ;
CLAVEL, F .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 241 (05) :651-662
[4]   Cancer vaccine strategies get bigger and better [J].
de Gruijl, TD ;
Curiel, DT .
NATURE MEDICINE, 1999, 5 (10) :1124-1125
[5]  
Firat H, 1999, EUR J IMMUNOL, V29, P3112, DOI 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO
[6]  
2-Q
[7]   Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences [J].
Follenzi, A ;
Ailles, LE ;
Bakovic, S ;
Geuna, M ;
Naldini, L .
NATURE GENETICS, 2000, 25 (02) :217-+
[8]   Monocyte-derived dendritic cells: development of a cellular processor for clinical applications [J].
Goxe, B ;
Latour, N ;
Bartholeyns, J ;
Romet-Lemonne, JL ;
Chokri, M .
RESEARCH IN IMMUNOLOGY, 1998, 149 (7-8) :643-646
[9]   Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro [J].
Gruber, A ;
Kan-Mitchell, J ;
Kuhen, KL ;
Mukai, T ;
Wong-Staal, F .
BLOOD, 2000, 96 (04) :1327-1333
[10]   GRANULOCYTES, MACROPHAGES, AND DENDRITIC CELLS ARISE FROM A COMMON MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II-NEGATIVE PROGENITOR IN MOUSE BONE-MARROW [J].
INABA, K ;
INABA, M ;
DEGUCHI, M ;
HAGI, K ;
YASUMIZU, R ;
IKEHARA, S ;
MURAMATSU, S ;
STEINMAN, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (07) :3038-3042